Diabetes
-
Permission granted by Abbott
Abbott data suggests GLP-1 drugs a ‘modest accelerator’ for CGMs: analysts
The analysis of U.S. insurance claims found people on GLP-1 therapy wear their FreeStyle Libre sensors more.
By Nick Paul Taylor • Sept. 29, 2023 -
Sarah Silbiger via Getty Images
Intarcia’s diabetes drug-device combo voted down again by FDA panel
The 19-member advisory committee unanimously voted against Intarcia in the review, citing cardiovascular and kidney safety concerns.
By Gwendolyn Wu • Sept. 25, 2023 -
Courtesy of Medtronic
Medtronic receives CE mark for CGM sensor, boosting challenge to Abbott and Dexcom
Medtronic has made the sensor smaller and eliminated the need for fingersticks to calibrate the device, bringing a challenger to market leaders Abbott and Dexcom.
By Nick Paul Taylor • Sept. 25, 2023 -
Permission granted by Bigfoot Biomedical
Q&ABigfoot CEO talks Abbott acquisition, future of diabetes tech
Jeffrey Brewer hopes to see more integrated solutions for people with diabetes, starting with the company’s partnership with Abbott.
By Elise Reuter • Sept. 15, 2023 -
dzika_mrowka via Getty Images
Insulin pump-makers grapple with questions about GLP-1s
The new class of weight loss drugs has caused a stock selloff, but is unlikely to “meaningfully change the long-term outlook for diabetes,” analysts wrote.
By Elise Reuter • Sept. 14, 2023 -
Courtesy of U.S. Food and Drug Administration
FDA proposes 3 guidances to improve 510(k) clearance process
The agency has made recommendations for selecting predicate devices, using clinical data and conducting performance testing for implants.
By Nick Paul Taylor • Sept. 7, 2023 -
Permission granted by Bigfoot Biomedical
Abbott to buy smart insulin pen cap maker Bigfoot
The planned acquisition could shift patients interested in smart pens to Abbott’s Libre CGMs, an analyst wrote.
By Elise Reuter • Sept. 6, 2023 -
Courtesy of Medtronic
Medtronic sued for allegedly sharing ‘treasure trove’ of diabetes patient data with Google
The plaintiff said disclosures to Google are “particularly problematic” because his use of Gmail meant his personal information was “automatically linked to his real identity.”
By Nick Paul Taylor • Sept. 5, 2023 -
Courtesy of Beta Bionics
Beta Bionics raises $100M to challenge Medtronic, Tandem for automated insulin dosing market
The company’s iLet Bionic Pancreas automates insulin dosing without requiring mealtime carb counting.
By Nick Paul Taylor • Sept. 1, 2023 -
Ethan Miller via Getty Images
Deep DiveWhy medtech firms are putting diabetes tech in consumer devices
As Abbott develops a line of wearable wellness devices, and Dexcom makes a CGM for people with diabetes who don’t take insulin, both companies are turning to new users for future growth.
By Elise Reuter • Updated Aug. 31, 2023 -
Medtronic raises earnings forecast amid supply chain, diabetes business improvements
The company also shared an update on the planned divestment of its monitoring and respiratory interventions segments.
By Elise Reuter • Aug. 22, 2023 -
Courtesy of Tandem
Tandem’s chief commercial officer to resign ahead of insulin pump rollout
Brian Hansen is stepping down as Tandem prepares to roll out its new Mobi pump.
By Elise Reuter • Aug. 21, 2023 -
Courtesy of Dexcom
Deep DiveDexcom, Abbott ramp up DTC marketing amid fight for share of growing diabetes market
As insurers cover continuous glucose monitors for more people, device-makers are taking a page from the pharma marketing playbook.
By Elise Reuter • Aug. 17, 2023 -
Courtesy of Insulet Corp.
Insulet claims EOFlow copied patch-pump design in patent suit
Insulet filed the lawsuit as competitor Medtronic plans to buy EOFlow for $738 million.
By Elise Reuter • Aug. 15, 2023 -
Permission granted by Senseonics
Senseonics seeks iCGM designation for implantable glucose monitor
The company also plans to submit results of a pivotal trial for a version of its device that can be worn for a year.
By Elise Reuter • Aug. 11, 2023 -
Douglas Cliff via Getty Images
Device volumes to hold up against threat of Wegovy, other GLP-1 drugs: analysts
Issues such as “nontrivial side effects, cost concerns and patient persistence” will mean physicians continue to use medical devices, analysts say.
By Nick Paul Taylor • Aug. 9, 2023 -
Courtesy of Dexcom
Dexcom hails CGM share gains as driver of 25% revenue growth in Q2
International market share gains and expanding coverage in the U.S. led the CGM maker to raise its revenue forecast for 2023.
By Nick Paul Taylor • July 28, 2023 -
Permission granted by Sanofi
Q&ASanofi’s Felix Lee talks DarioHealth partnership, future of digital health
The pharmaceutical company struck a strategic agreement with digital health company DarioHealth last year aimed at helping patients with diabetes manage their blood sugar levels.
By Elise Reuter • July 21, 2023 -
Courtesy of Abbott
Abbott Q2 net profit falls as weaker COVID test sales drag on revenue
Stronger medical device sales and a recovery in the infant formula business partly offset the impact of reduced COVID-19 testing.
By Susan Kelly • July 20, 2023 -
Courtesy of Tandem
Tandem’s Mobi insulin pump could reaccelerate growth next year: analyst
The device, which is smaller than Tandem’s past pumps, could drive more people to switch from insulin injections, an analyst with Craig-Hallum said.
By Elise Reuter • July 12, 2023 -
Permission granted by Medtronic
Medtronic secures Medicare coverage for MiniMed 780G insulin pump
Medtronic has begun processing orders and will start shipping devices over the next few weeks.
By Nick Paul Taylor • July 10, 2023 -
Permission granted by Becton Dickinson
BD to shed 60 jobs as COVID demand, diabetes spinoff affect manufacturing plant
The cuts are the latest in a wave of workforce reductions by medtech companies including Abbott Laboratories, Cook Medical, Illumina and Thermo Fisher Scientific.
By Nick Paul Taylor • July 7, 2023 -
Courtesy of Dexcom
Q&A
Q&A: Dexcom’s Lawver shares strategy behind CGM for non-insulin users
The continuous glucose monitor in development for people with Type 2 diabetes who don’t take insulin could expand the CGM market to 25 million more people in the U.S., the company’s new chief commercial officer said.
By Elise Reuter • June 30, 2023 -
Mario Tama via Getty Images
Diabetes remains fastest-growing medtech market despite some risk from new drugs: analysts
The medicines could apply “short-lived pressures” to medtech companies by affecting the use of insulin, Mizuho analysts say.
By Nick Paul Taylor • June 30, 2023 -
ClarkandCompany via Getty Images
More than 1 billion people could have diabetes by 2050, study says
A pair of studies published in the Lancet show that spending on diabetes care is expected to rise, but more work is needed to address structural inequities that affect access to treatment.
By Elise Reuter • June 26, 2023
